» Articles » PMID: 30063250

In Vivo Characterization of White Matter Pathology in Premanifest Huntington's Disease

Overview
Journal Ann Neurol
Specialty Neurology
Date 2018 Aug 1
PMID 30063250
Citations 30
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: Huntington's disease (HD) is a monogenic, fully penetrant neurodegenerative disorder, providing an ideal model for understanding brain changes occurring in the years prior to disease onset. Diffusion tensor imaging (DTI) studies show widespread white matter disorganization in the early premanifest stages (pre-HD). However, although DTI has proved informative, it provides only limited information about underlying changes in tissue properties. Neurite orientation dispersion and density imaging (NODDI) is a novel magnetic resonance imaging (MRI) technique for characterizing axonal pathology more specifically, providing metrics that separately quantify axonal density and axonal organization. Here, we provide the first in vivo characterization of white matter pathology in pre-HD using NODDI.

Methods: Diffusion-weighted MRI data that support DTI and NODDI were acquired from 38 pre-HD and 45 control participants. Using whole-brain and region-of-interest analyses, NODDI metrics were compared between groups and correlated with clinical scores of disease progression. Whole-brain changes in DTI metrics were also examined.

Results: The pre-HD group displayed widespread reductions in axonal density compared with control participants; this correlated with measures of clinical disease progression in the body and genu of the corpus callosum. There was also evidence in the pre-HD group of increased coherence of axonal packing in the white matter surrounding the basal ganglia.

Interpretation: Our findings suggest that reduced axonal density is one of the major factors underlying white matter pathology in pre-HD, coupled with altered local organization in areas surrounding the basal ganglia. NODDI metrics show promise in providing more specific information about the biological processes underlying HD and neurodegeneration per se. Ann Neurol 2018;84:497-504.

Citing Articles

Microstructural Changes in the Corpus Callosum in Neurodegenerative Diseases.

Albadawi E Cureus. 2024; 16(8):e67378.

PMID: 39310519 PMC: 11413839. DOI: 10.7759/cureus.67378.


White Matter Microstructure Changes Revealed by Diffusion Kurtosis and Diffusion Tensor Imaging in Mutant Huntingtin Gene Carriers.

Yin J, Liu Y, Li H, Burgunder J, Huang Y J Huntingtons Dis. 2024; 13(3):301-313.

PMID: 38905054 PMC: 11494636. DOI: 10.3233/JHD-240018.


Neuroimaging to Facilitate Clinical Trials in Huntington's Disease: Current Opinion from the EHDN Imaging Working Group.

Hobbs N, Papoutsi M, Delva A, Kinnunen K, Nakajima M, Van Laere K J Huntingtons Dis. 2024; 13(2):163-199.

PMID: 38788082 PMC: 11307036. DOI: 10.3233/JHD-240016.


Toward diffusion tensor imaging as a biomarker in neurodegenerative diseases: technical considerations to optimize recordings and data processing.

Muller H, Kassubek J Front Hum Neurosci. 2024; 18:1378896.

PMID: 38628970 PMC: 11018884. DOI: 10.3389/fnhum.2024.1378896.


Disentangling the neurobiological bases of temporal impulsivity in Huntington's disease.

Pardina-Torner H, De Paepe A, Garcia-Gorro C, Rodriguez-Dechicha N, Vaquer I, Calopa M Brain Behav. 2024; 14(3):e3335.

PMID: 38450912 PMC: 10918610. DOI: 10.1002/brb3.3335.


References
1.
Penney Jr J, Vonsattel J, Macdonald M, Gusella J, Myers R . CAG repeat number governs the development rate of pathology in Huntington's disease. Ann Neurol. 1997; 41(5):689-92. DOI: 10.1002/ana.410410521. View

2.
Kloppel S, Draganski B, Golding C, Chu C, Nagy Z, Cook P . White matter connections reflect changes in voluntary-guided saccades in pre-symptomatic Huntington's disease. Brain. 2007; 131(Pt 1):196-204. DOI: 10.1093/brain/awm275. View

3.
Burzynska A, Jiao Y, Knecht A, Fanning J, Awick E, Chen T . White Matter Integrity Declined Over 6-Months, but Dance Intervention Improved Integrity of the Fornix of Older Adults. Front Aging Neurosci. 2017; 9:59. PMC: 5352690. DOI: 10.3389/fnagi.2017.00059. View

4.
Ross C, Tabrizi S . Huntington's disease: from molecular pathogenesis to clinical treatment. Lancet Neurol. 2010; 10(1):83-98. DOI: 10.1016/S1474-4422(10)70245-3. View

5.
Gregory S, Cole J, Farmer R, Rees E, Roos R, Sprengelmeyer R . Longitudinal Diffusion Tensor Imaging Shows Progressive Changes in White Matter in Huntington's Disease. J Huntingtons Dis. 2016; 4(4):333-46. DOI: 10.3233/JHD-150173. View